Comparison of differences in blood laboratory results between acute promyelocytic leukemia and acute promyelocytic leukemia+FLT3-internal tandem duplication patients

Cytogenetic and FMS-Like Tyrosine Kinase 3 Mutation Analyses in Acute Promyelocytic Leukemia Patients

Background: The secondary genetic changes other than the promyelocytic leukemia-retinoic acid receptor (PML-RARA) fusion gene may contribute to the acute promyelocytic leukemogenesis. Chromosomal alterations and mutation of FLT3 (FMS-like tyrosine kinase 3) tyrosine kinase receptor are the frequent genetic alterations in acute myeloid leukemia. However, the prognostic significance of FLT3 mutat...

Acute myeloid leukemia and acute promyelocytic leukemia.

The therapeutic approach to the patient with acute myeloid leukemia (AML) currently evolves toward new frontiers. This is particularly apparent from the entree of high-throughput diagnostic technologies and the identification of prognostic and therapeutic targets, the introduction of therapies in genetically defined subgroups of AML, as well as the influx of investigational approaches and novel...

Acute Promyelocytic Leukemia (APL): Comparison Between Children and Adults

The outcome of adults and children with Acute Promyelocytic Leukemia (APL) has dramatically changed since the introduction of all trans retinoic acid (ATRA) therapy. Based on the results of several multicenter trials, the current recommendations for the treatment of patients with APL include ATRA and anthracycline-based chemotherapy for the remission induction and consolidation, and ATRA combin...

Acute promyelocytic leukemia?

Briefly, the important clinical findings were as follows: A 10 year old white girl, acutely ill, febrile and showing disseminated skin purpura. There was no visceromegaly. The disease had apparently started 3 weeks before, with epistaxis and other purpuric manifestations. Laboratory findings showed severe anemia and thrombocytopenia with a leukocyte count of 3500 per cu. mm. The differential co...

[Acute promyelocytic leukemia].